Cart
sales@molnova.com
AZD-7624
CAS No. 1095004-78-6
AZD-7624( AZD7624 )
Catalog No. M10370 CAS No. 1095004-78-6
AZD-7624 is a potent, selective, inhaled p38α MAPK inhibitor with pIC50 of 10.0.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 147 | Get Quote |
|
| 10MG | 237 | Get Quote |
|
| 25MG | 480 | Get Quote |
|
| 50MG | 698 | Get Quote |
|
| 100MG | 972 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAZD-7624
-
NoteResearch use only, not for human use.
-
Brief DescriptionAZD-7624 is a potent, selective, inhaled p38α MAPK inhibitor with pIC50 of 10.0.
-
DescriptionAZD-7624 is a potent, selective, inhaled p38α MAPK inhibitor with pIC50 of 10.0, displays 15-fold selectivity for p38α over p38β MAPK and >10,000-fold selectivity over p38γ and p38δ MAPK; inhibits LPS-induced TNF-α and IL-6 release in human alveolar macrophages pIC50 of 9.2 and 8.8, respectively; shows potential for prevention of exacerbations in COPD.COPD Phase 2 Discontinued.
-
In VitroAZD7624 is an inhaled p38 inhibitor, with potent anti-inflammatory activity. AZD7624 inhibits LPS-induced TNFα in human mononuclear cells, in whole blood as well as in alveolar macrophages in vitro, with pIC50s of 8.4, 8.1, and 9.0.
-
In Vivo——
-
SynonymsAZD7624
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38 MAPK
-
Research AreaInflammation/Immunology
-
IndicationCOPD
Chemical Information
-
CAS Number1095004-78-6
-
Formula Weight491.56
-
Molecular FormulaC27H30FN5O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (127.15 mM)
-
SMILESO=C(NC1CC1)C2=CC(N3C(C(NC4(C5=CC=CC=C5OCCNC)CC4)=NC=C3)=O)=C(C)C(F)=C2
-
Chemical NameN-cyclopropyl-3-fluoro-4-methyl-5-(3-((1-(2-(2-(methylamino)ethoxy)phenyl)cyclopropyl)amino)-2-oxopyrazin-1(2H)-yl)benzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Patel NR, et al. Int J Chron Obstruct Pulmon Dis. 2018 Mar 27;13:1009-1019.
2. Pehrson R, et al. Pharmacol Exp Ther. 2018 Mar 16. pii: jpet.117.246132.
molnova catalog
related products
-
VX-745
A potent and selective p38α kinase inhibitor with IC50 of 9 nM; shows 20-fold selectivity for p38α over p38β (Ki=220 nM) and no significant inhibition for MAP kinases (with the exception of MKK6).
-
mulberroside B
Antitussive, antiasthmatic, hypoglycemic, anti - tumor, treatment of gout.
-
RWJ 67657
A potent, selective, orally active p38 MAPK inhibitor that inhibits the production of TNF-α and IL-1β by LPS-stimulated human PBMCs with IC50 of 3 and 11 nM, respectively.
